NasdaqCM - Nasdaq Real Time Price USD

ZyVersa Therapeutics, Inc. (ZVSA)

4.4872 -0.3728 (-7.67%)
At close: May 17 at 4:00 PM EDT
4.5500 +0.06 (+1.40%)
After hours: May 17 at 7:10 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
14,420.7740
14,420.7740
13,013.0640
7,704.3760
11,833.0580
Operating Income
-14,420.7740
-14,420.7740
-13,013.0640
-7,704.3760
-11,833.0580
Net Non Operating Interest Income Expense
0.4570
0.4570
-427.5420
-821.3660
-516.4500
Other Income Expense
-93,333.4590
-93,333.4590
-607.0010
441.5810
-333.6580
Pretax Income
-107,753.7760
-107,753.7760
-14,047.6070
-8,084.1610
-12,683.1660
Tax Provision
-9,455.8300
-9,455.8300
--
--
--
Net Income Common Stockholders
-106,246.1550
-106,246.1550
-24,063.4440
-8,084.1610
-12,683.1660
Diluted NI Available to Com Stockholders
-106,246.1550
-106,246.1550
-24,063.4440
-8,084.1610
-12,683.1660
Basic EPS
-1.09k
--
-346.10
-139.88
-183.27
Diluted EPS
-1.09k
--
-346.10
-139.88
-183.27
Basic Average Shares
97.5030
--
69.2050
57.7920
69.2050
Diluted Average Shares
97.5030
--
69.2050
57.7920
69.2050
Total Operating Income as Reported
-107,754.2330
-107,754.2330
-13,013.0640
-7,704.3760
-11,833.0580
Total Expenses
14,420.7740
14,420.7740
13,013.0640
7,704.3760
11,833.0580
Net Income from Continuing & Discontinued Operation
-98,297.9460
-98,297.9460
-14,047.6070
-8,084.1610
-12,683.1660
Normalized Income
-13,177.8314
-13,177.8314
-13,440.6060
-8,525.7420
-12,349.5080
Interest Income
0.4570
0.4570
--
--
--
Interest Expense
582.5370
--
427.5420
821.3660
516.4500
Net Interest Income
0.4570
0.4570
-427.5420
-821.3660
-516.4500
EBIT
-14,420.7740
-14,420.7740
-13,620.0650
-7,262.7950
-12,166.7160
EBITDA
-14,410.3740
-14,410.3740
-13,610.1970
-7,252.3950
-12,156.3160
Reconciled Depreciation
10.4000
10.4000
9.8680
10.4000
10.4000
Net Income from Continuing Operation Net Minority Interest
-98,297.9460
-98,297.9460
-14,047.6070
-8,084.1610
-12,683.1660
Total Unusual Items Excluding Goodwill
-93,333.4590
-93,333.4590
-607.0010
441.5810
-333.6580
Total Unusual Items
-93,333.4590
-93,333.4590
-607.0010
441.5810
-333.6580
Normalized EBITDA
78,923.0850
78,923.0850
-13,003.1960
-7,693.9760
-11,822.6580
Tax Rate for Calcs
0.0001
0.0001
--
--
--
Tax Effect of Unusual Items
-8,213.3444
-8,213.3444
--
--
--
12/31/2020 - 2/11/2022

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SPRC SciSparc Ltd.
1.2200
+1.67%
 
VRAX Virax Biolabs Group Limited
0.8395
+4.94%
 
PXMD PaxMedica, Inc.
0.2401
-1.50%
 
CDIO Cardio Diagnostics Holdings, Inc.
0.7300
-12.99%
 
CMND Clearmind Medicine Inc.
1.2200
-5.43%
 
QNRX Quoin Pharmaceuticals, Ltd.
0.7600
-2.06%
 
REVB Revelation Biosciences, Inc.
2.0200
+8.60%
 
TCBP TC Biopharm (Holdings) Plc
1.1300
-0.88%
 
ELEV Elevation Oncology, Inc.
3.6100
0.00%
 
PALI Palisade Bio, Inc.
6.36
-1.55%